iRadimed Corp. (NASDAQ:IRMD) – Equities research analysts at Roth Capital issued their Q1 2017 earnings per share estimates for iRadimed Corp. in a research report issued on Wednesday. Roth Capital analyst C. Lewis anticipates that the firm will earn $0.03 per share for the quarter. Roth Capital currently has a “Neutral” rating and a $11.50 target price on the stock. Roth Capital also issued estimates for iRadimed Corp.’s Q2 2017 earnings at $0.04 EPS, Q3 2017 earnings at $0.04 EPS, Q4 2017 earnings at $0.07 EPS and FY2017 earnings at $0.18 EPS.
Separately, Zacks Investment Research cut iRadimed Corp. from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 5th.
Shares of iRadimed Corp. (NASDAQ:IRMD) traded down 3.14% during mid-day trading on Friday, hitting $10.18. 55,689 shares of the stock were exchanged. iRadimed Corp. has a 12-month low of $9.76 and a 12-month high of $33.25. The stock’s 50 day moving average price is $17.11 and its 200-day moving average price is $18.13. The stock has a market capitalization of $108.64 million, a P/E ratio of 14.63 and a beta of 1.28.
iRadimed Corp. (NASDAQ:IRMD) last announced its quarterly earnings data on Friday, July 29th. The company reported $0.24 EPS for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.03. The business had revenue of $9.90 million for the quarter, compared to analyst estimates of $9.60 million. iRadimed Corp. had a net margin of 24.52% and a return on equity of 30.52%. The firm’s revenue for the quarter was up 30.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.16 earnings per share.
In other news, VP Steven M. Nardi sold 2,096 shares of iRadimed Corp. stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $17.11, for a total transaction of $35,862.56. Following the sale, the vice president now directly owns 1,996 shares in the company, valued at approximately $34,151.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 69.00% of the company’s stock.
Large investors have recently made changes to their positions in the company. Teachers Advisors Inc. raised its stake in shares of iRadimed Corp. by 43.3% in the second quarter. Teachers Advisors Inc. now owns 5,670 shares of the company’s stock valued at $123,000 after buying an additional 1,712 shares during the period. BlackRock Advisors LLC raised its stake in shares of iRadimed Corp. by 5.6% in the second quarter. BlackRock Advisors LLC now owns 8,343 shares of the company’s stock valued at $182,000 after buying an additional 443 shares during the period. California State Teachers Retirement System raised its stake in shares of iRadimed Corp. by 39.6% in the second quarter. California State Teachers Retirement System now owns 8,484 shares of the company’s stock valued at $185,000 after buying an additional 2,405 shares during the period. Mesirow Financial Investment Management Equity Management purchased a new stake in shares of iRadimed Corp. during the second quarter valued at $273,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in shares of iRadimed Corp. during the second quarter valued at $290,000. 20.74% of the stock is owned by institutional investors.
About iRadimed Corp.
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for iRadimed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.